1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Market Access Impact: Renal Cell Carcinoma (EU5)

Market Access Impact: Renal Cell Carcinoma (EU5)

  • May 2016
  • ID: 3866843
  • Format: PDF
  • Firstword Pharma

Summary

Table of Contents




Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them?
We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when oncologists can’t prescribe freely. The result: 5 of those brands saw a net loss.
But 3 of them made significant net gains. Is your brand one of them?
You’ll learn how market barriers affect share for 8 major treatments from Bayer/Amgen, Novartis, Pfizer, and Roche.
Plus you’ll see which brands your brand is losing share to, which ones you’re taking it from, and why—information you can use to compete more effectively.





Get Answers to Key Questions about RCC Drug Brands


Afinitor (everolimus; Novartis): Afinitor takes market share from only two brands. Which two?
Avastin (bevacizumab; Roche): Which brand takes more than twice as much share from Avastin as any other?
Inlyta (axitinib; Pfizer): Would eliminating market barriers help Inlyta catch up to Afinitor?
Nexavar (sorafenib; Bayer/Amgen): Are doctors who don’t prescribe either brand more likely to consider Nexavar or Inlyta?
Proleukin (aldesleukin; Novartis): Which two barriers do more doctors experience with Proleukin than any other brand?
Sutent (sunitinib; Pfizer): Which barrier is responsible for nearly a quarter of Sutent’s impressive share gain?
Torisel (temsirolimus; Pfizer): Only one market barrier earns Torisel a net share gain. Which one?
Votrient (pazopanib; Novartis): Votrient and Afinitor are just about equally prescribed. Which brand has the edge in market share?

Top Takeaways


Barriers cost most brands market share: Five of the eight surveyed brands saw a net share loss due to barriers. Only three saw net gains.
Eliminating barriers would tighten up the market: Especially the top of the market, where it would make a big dent in the #1 brand’s lead.
Most brands are heavily prescribed: A majority of doctors prescribe nearly all of the brands surveyed. The most prescribed brand has almost a 10% lead over its nearest rival.
Clear market share winner: of the three brands that gain share due to market barriers, one gains more than twice as much as the closest competitor.
Barrier effect varies widely: The number of doctors who experience each market barrier varies widely from brand to brand.
Reimbursement and guidelines have the greatest impact: barriers related to reimbursement, patient type restrictions, and guidelines affect more prescriptions than any others.
Brand awareness is high: With one exception, no more than 1% of doctors surveyed were unaware of any given brand.
Overall market access is good: In Europe, market barriers affect less than 20% of prescription decisions.

Exploring Market Access Issues
Market Access Impact: RCC explores key issues affecting RCC drug manufacturers. You’ll learn:

How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge
We surveyed 150 medical oncologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between April 4th and 11th, 2016.








Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Kidney Cancer Therapeutics & Diagnostics Market- Growth, Trends, and Forecasts (2020-2025)

  • $ 4250
  • August 2020
  • 134 pages

The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. - According ...

  • World
  • Europe
  • Renal Cancer
  • Cancer
  • Industry analysis
  • Smoking Prevalence
  • Cause-Specific Mortality Rate

Global Cancer Therapies Industry $ 5450 September 2020


ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on